Mahnoor Shafi

Mahnoor Shafi

Auto-generated profile, based on publicly available information

Mahnoor Shafi

Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in World Neurosurgery
Verified
Journal Article
Open access
MSMahnoor Shafi
Mahnoor Shafi
SBShrikar R. Badikol
Shrikar R. Badikol
JGJakob Gerstl
Jakob Gerstl
NNNoah Nawabi
Noah Nawabi
MSMadhav Sukumaran
Madhav Sukumaran
MAMohammad Ali Aziz-Sultan
Mohammad Ali Aziz-Sultan
Middle meningeal artery embolization (MMAE) is an established treatment option for chronic subdural hematoma. The aim of this systematic review and meta-analysis was to establish estimates of the pooled incidence for complications following MMAE. PubMed, Embase, and Cochrane were searched for studies reporting complications following MMAE through January 2023. A random effects model was used to calculate the pooled incidence of complications stratified based on whether studies excluded patients with comorbidities. Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist was followed. A final 34 studies containing 921 patients undergoing MMAE were included that reported 35 complications. Neurological complications were reported in 7 studies with an overall pooled incidence of 3.8% (95% confidence interval [CI]: 2.6%-5.5%). Across these studies, there was a pooled incidence of 4.9% (95% CI: 2.9%-8.0%), 3.0% (95% CI: 1.7%-5.3%), and 2.1% (95% CI: 0.4%-9.7%) in studies that did not exclude, did not mention, or excluded patients with comorbidities, respectively. Similarly, 7 studies reported cardiovascular complications with an overall pooled incidence of 3.6% (95% CI: 2.4%-5.4%), 4 studies reported infectious complications with an overall pooled incidence of 2.9% (95% CI: 1.9%-4.5%), and 3 studies reported for miscellaneous complications with an overall pooled incidence of 3.1% (95% CI: 2.0%-4.8%). Further subgroup analysis revealed the pooled incidence of cardiovascular complications was 3.2% (95% CI: 1.7%-6.1%) in studies that did not exclude patients with comorbidities, 4.1% (95% CI: 2.3%-7.1%) in studies that did not specify the exclusion of such patients, and 1.8% (95% CI: 0.2%-11.5%) in studies that excluded these patients. Similarly, the incidence of infectious complications was 3.3% (95% CI: 1.7%-6.2%), 2.7% (95% CI: 1.5%-5.0%), and 1.8% (95% CI: 0.2%-11.5%) across these groups, respectively. Miscellaneous complications were reported at 4.0% (95% CI: 2.2%-7.2%), 2.3% (95% CI: 1.1%-4.6%), and 3.1% (95% CI: 0.9%-10.1%), respectively. The published literature suggests that MMAE is a generally well-tolerated procedure with a low risk of significant complications.

28 March 2025 in European Spine Journal
Verified
Journal Article
Closed access
PDF file
TATej D Azad
Tej D Azad
AKAhmet Kartal
Ahmet Kartal
MSMahnoor Shafi
Mahnoor Shafi
DLDaniel Lubelski
Daniel Lubelski
NTNicholas Theodore
Nicholas Theodore
TWTimothy F. F Witham
Timothy F. F Witham

9 April 2024 in World Neurosurgery
Verified
Journal Article
Closed access
AHAbdelrahman Mahmoud Hamouda
Abdelrahman Mahmoud Hamouda
Zach PenningtonZach Pennington
Zach Pennington
MSMahnoor Shafi
Mahnoor Shafi
MPMaria D. Astudillo Potes
Maria D. Astudillo Potes
HHHannah Hallak
Hannah Hallak
Benjamin D. ElderBenjamin D. Elder
Benjamin D. Elder

17 February 2024 in World Neurosurgery
Verified
Journal Article
Closed access
ASAlexander Swart
Alexander Swart
AHAbdelrahman Mahmoud Hamouda
Abdelrahman Mahmoud Hamouda
Zach PenningtonZach Pennington
Zach Pennington
AMAnthony L. Mikula
Anthony L. Mikula
MMMichael Martini
Michael Martini
Benjamin D. ElderBenjamin D. Elder
Benjamin D. Elder

13 January 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMahnoor Shafi
Mahnoor Shafi
ALAnna Baukje Lebouille-Veldman
Anna Baukje Lebouille-Veldman
COChady Omara
Chady Omara
NKNamita Kaler
Namita Kaler
JKJohn Kilgallon
John Kilgallon
CVCarmen Vleggeert-Lankamp
Carmen Vleggeert-Lankamp
Background: The effects of smoking on outcomes after spinal spondylodesis remain unclear due to conflicting findings in the existing literature. This meta-analysis aimed to evaluate the association between smoking and clinical as well as radiological outcomes following instrumented spinal fusion, and to examine differences based on smoking status, spinal region, and surgical extent. Methods: PubMed, Embase, and Cochrane were searched up to August 2024 for comparative studies reporting outcomes in smokers and non-smokers undergoing spinal fusion. Extracted outcomes included clinical scores (Oswestry Disability Index [ODI], Neck Disability Index [NDI], Visual Analog Scale [VAS] for pain), fusion rates, pseudoarthrosis, and complications. Pooled percent mean change from baseline and weighted incidences with 95% confidence intervals (CI) were calculated using a random-effects model. Subgroup analyses were performed by spinal region, number of operated levels, and smoking history (current, former, never). Results: Twenty-nine studies involving 6,687 patients were included. In most outcome measures, smokers showed smaller percent improvements than non-smokers. For instance, NDI improved by 42.8% (95% CI: 25.4–60.1%) in smokers vs. 49.7% (32.4–64.0%) in non-smokers; ODI improved by 48.6% (34.7–62.5%) vs. 56.5% (42.6–70.3%); and VAS back pain by 55.0% (29.7–80.2%) vs. 60.5% (35.2–85.7%). Fusion rates were lower in smokers (86.8%) than in non-smokers (95.1%), while pseudoarthrosis was more common in smokers (17.2% vs. 7.3%). Subgroup analyses revealed similar trends across spinal regions and surgical scope. A hierarchical pattern was observed, with never-smokers experiencing the most favorable outcomes, followed by former smokers. Conclusion: In most instances, smokers appeared to experience worse outcomes following instrumented spinal procedures compared to non-smokers, and a hierarchical pattern was notable, with current smokers experiencing the worst outcomes, followed by former smokers compared to never-smokers. Future well-designed studies with proper adjustment for confounding are needed to further confirm these findings.

5 January 2025 in World Neurosurgery
Verified
Journal Article
Open access
ECEthan Cott
Ethan Cott
CRChristian J. Rajkovic
Christian J. Rajkovic
JLJessica Lin
Jessica Lin
MSMahnoor Shafi
Mahnoor Shafi
JTJovanna Tracz
Jovanna Tracz
TWTimothy F. Witham
Timothy F. Witham
To 1) create a novel tissue-engineered bone graft comprising the osteoinductive oxysterol Oxy133 and 2) compare the osteogenic capability of this novel bone graft with bone graft substitutes previously examined. Oxy133 was homogeneously incorporated into a biomimetic (BioMim) bone graft substitute comprising extracellular matrix and calcium phosphates. Two iterations of the graft were created: one corresponding to an implant-dose of 2.0 mg Oxy133 (BioMim-Oxy133-Lo) and the other corresponding to an implant-dose of 20 mg Oxy133 (BioMim-Oxy133-Hi). Thirty-two male Sprague-Dawley rats were allocated randomly to 4 equally sized groups: 1) BioMim-Oxy133-Lo, 2) BioMim-Oxy133-Hi, 3) absorbable collagen sponge (ACS) with topically applied Oxy133 dissolved in dimethyl sulfoxide (ACS-Oxy133; 20 mg Oxy133/graft), and 4) ACS with topically applied recombinant human bone morphogenetic protein-2 (rhBMP-2) dissolved in water (ACS-rhBMP-2; 5.0 μg rhBMP-2/graft). All animals underwent L4-L5 posterolateral spinal fusion. Spines were harvested 8 weeks postoperatively and analyzed using micro-computed tomography imaging. Successful fusion was achieved in all animals. Grafts containing Oxy133 had significantly greater bone volume, percent of bone volume per tissue volume (%BV), bone surface density (BSD), and trabecular number (TbN) compared to ACS-rhBMP-2 (P < 0.01 for each). Animals treated with BioMim-Oxy133-Lo had the greatest %BV, BSD, and TbN (P < 0.001 for each), whereas animals treated with ACS-rhBMP-2 had the lowest %BV, BSD, TbN, and trabecular thickness (P < 0.001 for each). BioMim-Oxy133 is a novel bone graft that led to superior bone volume and quality compared to ACS-rhBMP-2 in a clinically translatable rat model of spinal fusion. Future work is needed to further evaluate this material as a safe and efficacious bone graft substitute.